Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2026)

Royalty Pharma has reported Total Current Liabilities for 8 years, with the latest figure at $535.7 million in Q1 2026.

• Quarterly Total Current Liabilities fell 54.71% year-over-year to $535.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535.7 million (down 54.71% YoY) and the FY2025 annual result came in at $636.2 million, down 49.25% from the prior year.
• Total Current Liabilities slipped to $535.7 million in Q1 2026 per RPRX's latest filing, from $636.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $1.3 billion in Q4 2024 and troughed at $124.6 million in Q1 2024.
• A 5-year average of $712.3 million and a median of $636.2 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 88.85% in 2024, then surged 849.52% in 2025.
• Over 5 years, Total Current Liabilities stood at $1.2 billion in 2022, then sank by 86.17% to $161.4 million in 2023, then surged by 676.82% to $1.3 billion in 2024, then tumbled by 49.25% to $636.2 million in 2025, then retreated by 15.8% to $535.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $535.7 million, $636.2 million, and $530.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.